Valeant Pharmaceuticals to Acquire Pedinol
News Apr 13, 2012
Revenue for 2011 was approximately $18 million and the transaction is expected to be immediately accretive.
"The Pedinol business will be a strong fit alongside Valeant's dermatology franchise," stated J. Michael Pearson, Valeant's chairman and chief executive officer. "The podiatry market has similar characteristics to the dermatology market that we find attractive from a risk and reward aspect, and expanding into this area is a natural extension of our topical formulation development capabilities. Pedinol has over 85 years of experience in podiatry and a highly regarded national field sales organization, which are both key as we prepare for broader expansion into this market. We expect Pedinol's established presence in the podiatry market to be a valuable asset for Valeant."
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE
Scientists Cloak Anti-Cancer Drugs in Particles to Target and Destroy Tumor CellsNews
Scientists now report results showing that, by cloaking anti-cancer drugs in a specially designed particle, they could target and destroy tumor cells deep inside a malignant mass in vitro.
Drug Capsule Delivers a Week’s Worth of HIV Drugs in a Single DoseNews
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose.READ MORE